Biotechnology

Organovo

Conference Minutes

09866

VIVS

ONVO

09863

02015

09868

01810

TSLA

01211

NVDA

XPEV

XIACY

81810

HXXD

81211

HYDD

002594

BYDDF

BYDDY

<p>Confident in achieving quarterly breakeven in the fourth quarter</p>

NIO-SW

North American Energy Par

Quanex Building Products

VivoSim Labs

LEAPMOTOR

ZEEKR Intelligent Tech

LI AUTO-W

XPENG-W

XIAOMI-W

Tesla

BYD COMPANY

NVIDIA

Edition

NIO Inc. USD OV

Li Auto

XPeng

Xiaomi Corporation

XIAOMI-WR

Xiaomi HK SDR 2to1

BYD COMPANY-R

BYD HK SDR 10to1

BYD Company Limited

BYD Company

Nio (3Q25 Minutes): Expects 20% vehicle gross margin in 2026, achieving full-year Non-GAAP profitability

Organovo Holdings Renamed to VivoSim Labs, Inc.

Organovo Holdings Shares Business Update on Innovative Treatments for Inflammatory Bowel Disease in San Diego

Organovo Holdings Issues 2,967,144 Shares of Common Stock, Generating Approximately $2.3 Million in Revenue

Eli Lilly Acquires Organovo's FXR314 Project, Expanding into the Inflammatory Bowel Disease Market

Eli Lilly Acquires Organovo's FXR Project to Advance Inflammatory Bowel Disease Treatment

Organovo released FY2025 Q3 earnings on February 19 (EST), actual revenue 24K USD (forecast 50K USD), actual EPS -2.2908 USD (forecast -2.4 USD)

Organovo released FY2025 9 Months Earnings on February 19 (EST) with actual revenue of 93K USD and EPS of -6.7506 USD

Organovo released FY2025 Q2 earnings on November 8 (EST), actual revenue 30K USD (forecast 50K USD), actual EPS -1.6998 USD (forecast -2.64 USD)

Organovo released FY2025 Semi-Annual Earnings on November 8, 2024 (EST) with actual revenue of 69K USD and EPS of -4.3282 USD

Organovo released FY2025 Q1 earnings on August 5 (EST), actual revenue 39 K USD (forecast 30 K USD), actual EPS -2.7599 USD (forecast -3.96 USD)

Organovo released FY2024 annual earnings on May 31 (EST), actual revenue 109 K USD (forecast 75 K USD), actual EPS -19.2513 USD (forecast -20.88 USD)

Organovo released FY2024 Q4 earnings on May 31 (EST), actual revenue 29 K USD (forecast 75 K USD), actual EPS -3.6441 USD (forecast -5.04 USD)

Organovo Holdings Announces Positive Results from Phase 2 Trial of FXR314 for Treating MASH Patients

Organovo released FY2024 Q3 earnings on February 8 (EST), actual revenue 5 K USD (forecast 75 K USD), actual EPS -4.7444 USD (forecast -4.92 USD)

Organovo released FY2024 9 Months Earnings on February 8 (EST), with actual revenue of 80K USD and EPS of -15.79 USD

Organovo released FY2024 Q2 earnings on November 9 (EST), actual revenue 0 USD (forecast 75 K USD), actual EPS -5.4972 USD (forecast -5.16 USD)

Organovo released FY2024 Semi-Annual Earnings on November 9, 2023 (EST) with actual revenue of 75K USD and EPS of -11.0421 USD

Organovo released FY2024 Q1 earnings on August 10 (EST), actual revenue 75K USD, actual EPS -5.5448 USD

Organovo released FY2023 Q4 earnings on July 14 (EST), with actual revenue of 162 K USD and EPS of -10.2702 USD

Organovo released FY2023 annual earnings on July 14 (EST), actual revenue 370 K USD, actual EPS -23.7699 USD

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

ADMA生物制药

Kiniksa Pharmaceuticals

Stoke Therapeutics

Rigel制药

OpGen

福泰制药

再生元制药

Argenx

阿里拉姆制药

百济神州

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap